Compare Stocks: GRCL, IRON, BEAM, and KOD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$27.48	$30.61	$15.60 ▼ $38.26	$2.84B	2.23	1.98 million shs	1.32 million shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
IRON Disc Medicine	$77.44	$73.59	$40.00 ▼ $99.50	$2.96B	1	350,312 shs	307,549 shs
KOD Kodiak Sciences	$45.37	$38.28	$7.68 ▼ $47.84	$2.84B	2.21	557,773 shs	510,691 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+7.68%	-15.91%	-13.45%	+55.96%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
IRON Disc Medicine	0.00%	+0.57%	+1.11%	+11.86%	+33.45%
KOD Kodiak Sciences	0.00%	+9.11%	+9.83%	+13.85%	+474.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$27.48	$30.61	$15.60 ▼ $38.26	$2.84B	2.23	1.98 million shs	1.32 million shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
IRON Disc Medicine	$77.44	$73.59	$40.00 ▼ $99.50	$2.96B	1	350,312 shs	307,549 shs
KOD Kodiak Sciences	$45.37	$38.28	$7.68 ▼ $47.84	$2.84B	2.21	557,773 shs	510,691 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+7.68%	-15.91%	-13.45%	+55.96%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
IRON Disc Medicine	0.00%	+0.57%	+1.11%	+11.86%	+33.45%
KOD Kodiak Sciences	0.00%	+9.11%	+9.83%	+13.85%	+474.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	78.31% Upside
GRCL Gracell Biotechnologies	0.00	N/A	N/A	N/A
IRON Disc Medicine	2.75	Moderate Buy	$106.00	36.88% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	6.11% Upside

Current Analyst Ratings Breakdown

Latest GRCL, IRON, BEAM, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$118.00 ➝ $120.00
8/3/2026	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $66.00
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IRON Disc Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	KOD Kodiak Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$47.00
7/7/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
6/15/2026	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$80.00 ➝ $85.00
6/10/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$88.00
5/21/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
5/14/2026	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$75.00 ➝ $80.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	20.31	N/A	N/A	$12.20 per share	2.25
GRCL Gracell Biotechnologies	$60K	12,415.83	N/A	N/A	$2.95 per share	3.47
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	N/A
GRCL Gracell Biotechnologies	-$88.08M	-$1.05	N/A	N/A	N/A	N/A	-37.40%	-31.24%	N/A
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	N/A
KOD Kodiak Sciences	-$229.97M	-$4.17	N/A	N/A	N/A	N/A	-253.85%	-81.48%	8/12/2026 (Estimated)

Latest GRCL, IRON, BEAM, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
GRCL Gracell Biotechnologies	0.02	7.73	7.73
IRON Disc Medicine	0.09	24.14	24.14
KOD Kodiak Sciences	N/A	3.54	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
GRCL Gracell Biotechnologies	N/A
IRON Disc Medicine	83.70%
KOD Kodiak Sciences	89.06%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
GRCL Gracell Biotechnologies	28.00%
IRON Disc Medicine	3.76%
KOD Kodiak Sciences	44.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
GRCL Gracell Biotechnologies	314	72.68 million	52.33 million	No Data
IRON Disc Medicine	30	38.16 million	36.95 million	Not Optionable
KOD Kodiak Sciences	90	62.58 million	34.79 million	Optionable

GRCL, IRON, BEAM, and KOD Headlines

Recent News About These Companies

Kodiak Sciences completes enrollment in phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation

August 8 at 10:59 AM | pharmabiz.comP

The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD

August 7 at 4:40 AM | marketbeat.com

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical ...

August 6, 2026 | finance.yahoo.com

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

August 6, 2026 | prnewswire.com

Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday

August 5, 2026 | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

August 5, 2026 | americanbankingnews.com

Kodiak Sciences Inc. (NASDAQ:KOD) Receives $42.14 Average PT from Brokerages

August 4, 2026 | americanbankingnews.com

Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $66.00 at JPMorgan Chase & Co.

August 3, 2026 | marketbeat.com

Janus Henderson Group PLC Raises Stake in Kodiak Sciences Inc. $KOD

August 2, 2026 | marketbeat.com

Renaissance Technologies LLC Lowers Stock Holdings in Kodiak Sciences Inc. $KOD

August 2, 2026 | marketbeat.com

57,400 Shares in Kodiak Sciences Inc. $KOD Acquired by Swiss National Bank

July 31, 2026 | marketbeat.com

Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Rating of "Moderate Buy" from Brokerages

July 30, 2026 | marketbeat.com

Kodiak Sciences (NASDAQ:KOD) Trading 6.6% Higher - What's Next?

July 17, 2026 | marketbeat.com

Y Intercept Hong Kong Ltd Sells 27,959 Shares of Kodiak Sciences Inc. $KOD

July 15, 2026 | marketbeat.com

Kodiak Sciences Inc.

June 30, 2026 | barrons.com

10 mid-cap US healthcare stocks with the strongest momentum grades

June 24, 2026 | msn.com

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

June 16, 2026 | seekingalpha.com

Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know

June 9, 2026 | fool.com

Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans

June 7, 2026 | finance.yahoo.com

Kodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

June 5, 2026 | seekingalpha.com

Kodiak Sciences Stockholders Back Directors and Governance Proposals

June 4, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRCL, IRON, BEAM, and KOD Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$27.48 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$27.49 +0.01 (+0.02%)

As of 07:50 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Disc Medicine NASDAQ:IRON

$77.44 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$77.51 +0.07 (+0.09%)

As of 07:20 AM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Kodiak Sciences NASDAQ:KOD

$45.37 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$45.70 +0.33 (+0.73%)

As of 07:52 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCL, IRON, BEAM, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCL, IRON, BEAM, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCL, IRON, BEAM, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRCL, IRON, BEAM, and KOD Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Gracell Biotechnologies NASDAQ:GRCL

Disc Medicine NASDAQ:IRON

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCL, IRON, BEAM, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCL, IRON, BEAM, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCL, IRON, BEAM, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRCL, IRON, BEAM, and KOD Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Gracell Biotechnologies NASDAQ:GRCL

Disc Medicine NASDAQ:IRON

Kodiak Sciences NASDAQ:KOD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools